RT Journal Article
SR Electronic
T1 RIPK1 Biallelic Activating Variants lead to Autoinflammatory Disease Driven by T cell Death
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.03.28.24304774
DO 10.1101/2024.03.28.24304774
A1 Dai, Jialin
A1 Jin, Taijie
A1 Su, Gaixiu
A1 Han, Xu
A1 Wang, Jun
A1 Liu, Chenlu
A1 Zheng, Wenjie
A1 Zhang, Qiuye
A1 Yang, Jun
A1 Guo, Li
A1 Zhang, Dan
A1 Li, Ming
A1 Xu, Yingjie
A1 Yue, Tong
A1 Wen, Min
A1 Zhu, Jia
A1 Kang, Min
A1 Lai, Jianming
A1 Wu, Feifei
A1 Wang, Shihao
A1 Zhang, Jiahui
A1 Lee, Pui Y.
A1 Yuan, Junying
A1 Yu, Xiaomin
A1 Zhou, Qing
YR 2024
UL http://medrxiv.org/content/early/2024/04/03/2024.03.28.24304774.abstract
AB Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) is a key regulator of cell fate decision between pro-survival signaling and programmed cell death. The activation of RIPK1 is extensively modulated by posttranslational modification, such as ubiquitination. RIPK1 overactivation mediates autoinflammatory diseases in humans. However, the role of RIPK1 ubiquitination in human autoinflammatory diseases has not been reported, and the mechanism mediating the interaction of cell death and autoinflammation is largely unknown. Here, we report two patients carrying compound heterozygous RIPK1 variants K377E/R390G with recurrent fevers, lymphadenopathy and skin rashes. Mechanistically, K377E and R390G mutations impaired ubiquitination of RIPK1, which suppresses the formation of TNFR1 signaling complex (TNF-RSC) and NF-κB activation, resulting in the loss of CD8+ T cells mediated by RIPK1 activation-induced cell death in the patients. We reveal that the death of CD8+ T cells promotes the secretion of TNF and IFNγ to activate monocytes and macrophages, which triggers further production of proinflammatory cytokines to amplify autoinflammation. Disruption of the communication between T cells and monocytes/macrophages through pharmacologic blockade of TNF and IFNγ attenuated proinflammatory cytokine production in macrophages. Collectively, our results demonstrate a crucial role of RIPK1 ubiquitination in regulating CD8+ T cell death and restraining autoinflammation. Our study demonstrates the mechanism for a group of autoinflammatory diseases mediated by RIPK1 activation-induced cell death, and highlights an important role of CD8+ T cells in driving autoinflammation.Competing Interest StatementJ.Y. is a consultant of Denali Therapeutics. The rest of authors declare no competing financial interests.Funding StatementThe works of Q.Z. were supported by grants 82225022, 32141004 and 32321002 from the National Natural Science Foundation of China. The works of X.Y. were supported by the Hundred-Talent Program of Zhejiang University. J.D. received grant 32300618 from the National Natural Science Foundation of China. J.W. received the grant 2023M733104 from China Postdoctoral Science Foundation. L.G. received the grant LHDMY23H100005 from Zhejiang Provincial Natural Science Foundation of China.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Patients were evaluated under protocols approved by Institutional Review Board and Ethical Committee at the Children's Hospital of Zhejiang University School of Medicine (protocol 2021-IRB-172).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe raw data of sequencing will be available prior to publication. The other source data that support the findings of this study are available from the corresponding author upon reasonable request.